title: Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?
abstract: The aim of the study was to examine the effect of androgen deprivation drugs, i.e. leuprolide and bicalutamide on the immune cross-talk between human peripheral blood mononuclear cells (PBMC) and cells from PC-3 and LNCaP human prostate cancer lines. PBMC, PC-3 and LNCaP were separately incubated without and with two androgen-deprivation drugs, i.e. leuprolide and bicalutamide, and the secretion of IL-1β, IL-6, IL-1ra and IL-10 was examined. In addition, the effect of both drugs on the production of those cytokines was carried out after 24 hours incubation of PBMC with both types of cancer cells. Leuprolide or bicalutamide did not affect the production of the cytokines by PBMC or by the prostate cancer cells from the two lines. Incubation of PBMC with PC-3 or LNCaP cells caused increased production of IL-1β, IL-6 and IL-10 as compared with PBMC incubated without malignant cells. While 10(-7) M and 10(-8) M of leuprolide caused a decreased secretion of IL-1β by PBMC previously incubated with prostate cancer cells without the drug, bicalutamide did not affect this PBMC activity at any drug concentration. This observation suggests the existence of an additional mechanism explaining the effect of androgen deprivation therapy in prostate cancer patients.
authors.affiliation: Department of Medicine C, Rabin Medical Center-Hasharon Hospital, Petah-Tiqva, Israel; Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
authors.forename: Hertzel
authors.initials: H
authors.lastname: Salman
authors.affiliation: Department of Medicine C, Rabin Medical Center-Hasharon Hospital, Petah-Tiqva, Israel; Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
authors.forename: Michael
authors.initials: M
authors.lastname: Bergman
authors.affiliation: Department of Medicine C, Rabin Medical Center-Hasharon Hospital, Petah-Tiqva, Israel; Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
authors.forename: Naava
authors.initials: N
authors.lastname: Blumberger
authors.affiliation: Laboratory for Immunology and Hematology Research, Rabin Medical Center-Hasharon Hospital, Petah-Tiqva, Israel; Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv, Israel. Electronic address: bermanm@clalit.org.il.
authors.forename: Meir
authors.initials: M
authors.lastname: Djaldetti
authors.affiliation: Laboratory for Immunology and Hematology Research, Rabin Medical Center-Hasharon Hospital, Petah-Tiqva, Israel; Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
authors.forename: Hanna
authors.initials: H
authors.lastname: Bessler
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000813:Anilides / Q000008:administration & dosage / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D002450:Cell Communication / Q000276:immunology; D045744:Cell Line, Tumor; D016207:Cytokines / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007378:Interleukins / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D016729:Leuprolide / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009570:Nitriles / Q000008:administration & dosage / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D014105:Tosyl Compounds / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D000970:Antineoplastic Agents; D016207:Cytokines; D007378:Interleukins; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D016729:Leuprolide
keywords: Bicalutamide; Inflammatory cytokines; LHRH agonist; Leuprolide; Mononuclear cells; PC-3 and LNCaP; Prostate cancer cells